Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

AWS’s framework will speed up the analysis of ElevateBio’s large protein datasets, hinting at promising drug candidates.

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

CRISPR leaders came together to celebrate the one-year anniversary of the Danaher-IGI Beacon for CRISPR Cures collaboration, ...

The study, published in Nucleic Acids Research, introduces BLU-VIPR, a method that allows researchers to control the gene-editing tool CRISPR using light. This innovation could significantly ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

With AWS on board, ElevateBio says that it can design high-level CRISPR proteins with improved therapeutic potential both for ...

Using gene editing with CRISPR-Cas9, the team has been able to study these proteins without altering ... Dec. 13, 2024 — Microorganisms produce a wide variety of natural products that can be ...

Beam Therapeutics said Monday that it used a form of CRISPR called base editing to correct, in several patients, a mutation that drives a debilitating lung condition that may affect tens of ...